title: Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case-control study.
abstract: BACKGROUND
  It has been shown that peroxisome proliferator-activated receptors (PPAR) have physiological and pharmacological ligands. The objective is to assess the association between thiazolidinediones (TZDs) and the occurrence of gastric cancer.
  
  
  METHODS
  We conducted a population-based nested case-control study. Data were retrospectively collected from the National Health Insurance Research Database (NHIRD). The cases consisted of all diabetes mellitus (DM) patients aged 30 to 99 years, and who had a first time diagnosis of gastric cancer in the study cohort. The controls were matched to cases by age, sex, and index date. The adjusted odds ratio (OR) and 95% confidence interval (CI) were estimated by using multiple logistic regression.
  
  
  RESULTS
  Records from 357 gastric cancer and 1,428 selected matched controls were included in the analyses of gastric cancer risk. A total of 7% or 9.5% of the cases and 10.8% or 14.8% of the controls had used any quantity of at least 2 prescriptions for pioglitazone or rosiglitazone, respectively. After adjusting for possible confounders, pioglitazone (OR = 0.93, P > 0.05) and rosiglitazone (OR = 1.21, P > 0.05), had no significant association of decreasing gastric cancer. After adjusting for possible confounders, pioglitazone (OR = 0.70, P > 0.05) or rosiglitazone (OR = 0.79, P > 0.05), had no significant trend toward decreasing gastric cancer risk with increasing cumulative doses ≥ 260 defined daily doses (DDDs), respectively. Moreover, adjusting for possible confounders pioglitazone (OR = 0.68, P > 0.05) or rosiglitazone (OR = 0.74, P > 0.05) had no significant trend toward decreasing gastric cancer risk with increasing cumulative doses ≥ 1 year, respectively.
  
  
  CONCLUSIONS
  Our results did not show evidence to support that TZD derivatives in DM patients reduces gastric cancer occurrence.
authors.affiliation: Institute of Public Health & Department of Public Health, National Yang-Ming University, Taipei, Taiwan. hyhu@ym.edu.tw.
authors.forename: Shen-Shong
authors.initials: SS
authors.lastname: Chang
authors.forename: Hsiao-Yun
authors.initials: HY
authors.lastname: Hu
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D011159:Population Surveillance; D000077154:Rosiglitazone; D013274:Stomach Neoplasms / Q000139:chemically induced* / Q000453:epidemiology*; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone
references.citation: Nature. 2000 May 25;405(6785):421-4
references.pmid: 10839530
references.citation: Expert Opin Investig Drugs. 2007 Apr;16(4):413-7
references.pmid: 17371190
references.citation: World J Gastroenterol. 2009 Aug 21;15(31):3874-83
references.pmid: 19701967
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Br J Cancer. 2001 Jun 15;84(12):1640-7
references.pmid: 11401318
references.citation: Acta Diabetol. 2010 Jun;47(2):87-95
references.pmid: 20376506
references.citation: Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11
references.pmid: 9671760
references.citation: J Clin Endocrinol Metab. 2001 May;86(5):2170-7
references.pmid: 11344222
references.citation: Cancer Treat Rev. 2004 Oct;30(6):545-54
references.pmid: 15325034
references.citation: World J Gastroenterol. 2009 Jan 21;15(3):310-20
references.pmid: 19140230
references.citation: Gastroenterology. 2009 Nov;137(5):1641-8.e1-2
references.pmid: 19664631
references.citation: CA Cancer J Clin. 2006 Sep-Oct;56(5):254-81; quiz 313-4
references.pmid: 17005596
references.citation: J Clin Endocrinol Metab. 2002 Oct;87(10):4728-35
references.pmid: 12364466
references.citation: Gut. 2004 Mar;53(3):331-8
references.pmid: 14960510
references.citation: Cancer Res. 2005 Jun 1;65(11):4769-74
references.pmid: 15930296
references.citation: BMC Health Serv Res. 2007 Oct 25;7:175
references.pmid: 17961256
references.citation: Pharmacotherapy. 2011 Mar;31(3):239-47
references.pmid: 21361733
references.citation: Am J Gastroenterol. 2008 Mar;103(3):510-4
references.pmid: 18341483
references.citation: Lancet Oncol. 2009 Nov;10(11):1033-4
references.pmid: 19891056
references.citation: Diabetes. 2008 Aug;57(8):2149-57
references.pmid: 18443198
references.citation: Nature. 1998 Jan 1;391(6662):82-6
references.pmid: 9422509
references.citation: Hepatology. 2012 May;55(5):1462-72
references.pmid: 22135104
references.citation: Diabetes Care. 2010 Jul;33(7):1674-85
references.pmid: 20587728
references.citation: Expert Opin Investig Drugs. 2003 Dec;12(12):1925-37
references.pmid: 14640937
references.citation: J Pharmacol Sci. 2004 Oct;96(2):134-43
references.pmid: 15492468
references.citation: J Biol Chem. 2001 Aug 17;276(33):31059-66
references.pmid: 11397815
references.citation: IUBMB Life. 2002 Jun;53(6):303-8
references.pmid: 12625369
references.citation: Lancet Oncol. 2008 Nov;9(11):1039-47
references.pmid: 18835745
references.citation: J Med Chem. 2000 Feb 24;43(4):527-50
references.pmid: 10691680
references.citation: FEBS Lett. 1999 Jul 16;455(1-2):135-9
references.pmid: 10428487
references.citation: BMC Med Res Methodol. 2005 Jan 25;5(1):5
references.pmid: 15670334
references.citation: Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):745-51
references.pmid: 20582905
references.citation: Int J Cancer. 2001 Oct 15;94(2):153-6
references.pmid: 11668491
references.citation: Lancet. 1998 Nov 28;352(9142):1767-70
references.pmid: 9848368
references.citation: J Clin Invest. 2003 May;111(9):1381-8
references.pmid: 12727930